<DOC>
	<DOCNO>NCT00099008</DOCNO>
	<brief_summary>RATIONALE : Chemoprevention therapy use certain drug try prevent development recurrence cancer . The use genistein may effective prevent breast endometrial cancer . PURPOSE : This randomized phase I trial study effectiveness genistein prevent breast endometrial cancer healthy postmenopausal woman .</brief_summary>
	<brief_title>Genistein Preventing Breast Endometrial Cancer Healthy Postmenopausal Women</brief_title>
	<detailed_description>OBJECTIVES : - Compare effect genistein vs placebo DNA damage apoptosis conduct COMET , TUNEL , Caspase-3 , AP site assay healthy postmenopausal woman . - Compare effect drug gene expression estrogen-sensitive tissue oligoarray profile participant . - Determine effect genistein estrogenic effect self-reported side effect , measurement sex hormone-binding globulin , follicle-stimulating hormone , luteinizing hormone , estrogen level , expression know estrogen-sensitive gene participant . OUTLINE : This randomize , double-blind , placebo-controlled study . Participants stratify accord study ID number . Participants randomize 1 2 treatment arm . - Arm I : Participants receive oral genistein twice daily day 1-84 . - Arm II : Participants receive oral placebo twice daily day 1-84 . In arm , treatment continue absence dysplasia , malignancy , unacceptable toxicity , gross noncompliance . Participants follow day 7 , 14 , 28 , 56 , 84 study treatment day 28 completion study treatment . PROJECTED ACCRUAL : A total 30 participant ( 20 arm I 10 arm II ) accrue study .</detailed_description>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Genistein</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Healthy participant Papanicolaou test ( pap smear ) normal within past 13 month Mammogram normal within past 13 month No history breast cancer Not highrisk ( 5year risk &lt; 1.9 % ) breast cancer accord NCI 's Breast Cancer Risk Assessment Tool Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age 45 70 Sex Female Menopausal status Postmenopausal Last spontaneous menstrual bleeding &gt; 12 month ago Performance status ECOG 02 Life expectancy Not specify Hematopoietic WBC ≥ 3,500/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic Bilirubin ≤ 2.0 mg/dL ALT AST &lt; 2 time normal No significant abnormality liver physical exam Renal Creatinine &lt; 2.0 mg/dL Cardiovascular No significant cardiac disease No New York Heart Association class III IV heart disease No significant abnormality heart physical exam Pulmonary No significant abnormality lung physical exam Other Body mass index &lt; 35 Folliclestimulating hormone &gt; 27 mIU/mL Thyroid endocrine function test normal Alcohol intake ≤ 2 drinks/day ≤14 drinks/week Not pregnant No intermediate equol value ( ≥10 ug/L ≤ 20 ug/L ) soy challenge No history seizures No significant abnormality spleen abdominal organ physical exam No neurologic abnormality physical exam No significant metabolic abnormality biochemical screen No history substance abuse addiction No tobacco use No diet contain &gt; 20 mg genistein/day &gt; 40 mg isoflavone/day No known intolerance soy No serious medical illness No active malignancy malignancy initially diagnose within past 2 year except curatively treat nonmelanoma skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy More 2 year since prior chemotherapy No concurrent chemotherapy Endocrine therapy More 3 month since prior hormonal estrogen therapy More 3 month since prior tamoxifen selective estrogenreceptor modulators More 1 month since prior supplement contain phytoestrogens estrogenic side effect ( soy isoflavones PCSPECS ) No concurrent thyroid medication Other concurrent endocrine medication allow provided medication initiate ≥ 3 month study entry AND participant stable regimen past 3 month Radiotherapy Not specify Surgery No prior hysterectomy oophorectomy Other More 3 month since prior antibiotic</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>endometrial cancer</keyword>
</DOC>